| Pair Name | Tanshinone I, Lenalidomide | ||
| Phytochemical Name | Tanshinone I (PubChem CID: 114917 ) | ||
| Anticancer drug Name | Lenalidomide (PubChem CID: 216326 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Tanshinone I, Lenalidomide | |||
| Disease Info | [ICD-11: 2A83.1] | Multiple myeloma | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | ACD | hsa65057 |
| Down-regulation | Expression | TERF2IP | hsa54386 | |
| Down-regulation | Expression | TNKS | hsa8658 | |
| In Vitro Model | RPMI-8226 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_0014 |
| U266B1 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_0566 | |
| Result | Combination of TanI with standard chemotherapeutic drug Len, potentiates cell death in myeloma cells | |||
| No. | Title | Href |
|---|---|---|
| 1 | Novel combination of tanshinone I and lenalidomide induces chemo-sensitivity in myeloma cells by modulating telomerase activity and expression of shelterin complex and its associated molecules. Mol Biol Rep. 2018 Dec;45(6):2429-2439. doi: 10.1007/s11033-018-4409-z. | Click |
